Significance is given as unadjusted P values, compared with placebo: *P≤0.05, **P<0.01, ***P<0.001.
For RA and PsA populations, LS mean changes from baseline in EQ-5D PD domain were analyzed using a repeated-measures model with fixed effects for treatment group, visit, interaction of the treatment group by visit, geographic location, study (if more than one), and baseline value. The model used a common unstructured variance-covariance matrix, without imputation for missing data. Within this, two models were used: 1) up to month 3 the two placebo-to-tofacitinib sequences were combined into a single placebo group (pooled placebo group); 2) after month 3 (including all post-baseline data up to month 6) the placebo-totofacitinib sequences were kept separate. For the AS population, treatment comparisons between tofacitinib (5 mg or 10 mg BID) and placebo at week 12 were made using an analysis of covariance model, with fixed effects for treatment and baseline value; missing values were imputed by last observation carried forward. † EQ-5D PD: range 1 (no pain or discomfort) to 3 (extreme pain or discomfort). AS, ankylosing spondylitis; BID, twice daily; csDMARD, conventional synthetic diseasemodifying antirheumatic drug; EQ-5D, EuroQol Five Dimensions questionnaire; FAS, full analysis set; IR, inadequate response; LS, least squares; NSAID, non-steroidal antiinflammatory drug; PD, Pain/Discomfort; PsA, psoriatic arthritis; RA, rheumatoid arthritis; SE, standard error; TNFi, tumor necrosis factor inhibitor. 
